Anebulo Pharmaceuticals Announces Oversubscribed Self-Tender Offer Results

Anebulo Pharmaceuticals ( (ANEB) ) has shared an update.

On January 27, 2026, Anebulo Pharmaceuticals reported preliminary results from its voluntary self-tender offer for up to 300,000 shares of its common stock at $3.50 per share in cash, following the offer’s expiration on January 26, 2026. The offer was significantly oversubscribed, with about 4.9 million shares properly tendered, leading the company to expect pro rata acceptance of approximately 300,000 shares—about 0.73% of shares outstanding as of January 26—at an estimated aggregate cost of $1.05 million, excluding fees and expenses. A preliminary proration factor of roughly 3.5% is expected, with “odd lot” tenders to be accepted in full; final share counts and proration will be confirmed after the guaranteed delivery period, and accepted shares will be paid for in cash while unpurchased shares will be returned promptly. The oversubscription suggests robust shareholder interest in the liquidity event and will result in a modest reduction in Anebulo’s share count, with limited but targeted impact on capital allocation and ownership structure.

The most recent analyst rating on (ANEB) stock is a Hold with a $1.00 price target. To see the full list of analyst forecasts on Anebulo Pharmaceuticals stock, see the ANEB Stock Forecast page.

Spark’s Take on ANEB Stock

According to Spark, TipRanks’ AI Analyst, ANEB is a Neutral.

The score is primarily weighed down by weak financial fundamentals (no revenue, ongoing losses and cash burn) and bearish technicals (price far below major moving averages with negative MACD). Valuation is constrained by the lack of earnings and no dividend, and the going-private/delisting-related event adds additional uncertainty.

To see Spark’s full report on ANEB stock, click here.

More about Anebulo Pharmaceuticals

Anebulo Pharmaceuticals, Inc. is a clinical-stage pharmaceutical company focused on developing novel treatments for cannabis-induced toxicity. Its lead product candidate, selonabant, a competitive CB1 receptor antagonist, has completed a Phase 2 trial for acute cannabinoid intoxication in adults, and the company is currently prioritizing an intravenous formulation aimed at pediatric patients with acute cannabis-induced toxicity, with a Phase 1 single ascending dose study of IV selonabant initiated in September 2025.

Average Trading Volume: 61,638

Technical Sentiment Signal: Sell

Current Market Cap: $44.37M

See more insights into ANEB stock on TipRanks’ Stock Analysis page.